Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
This study is to establish a pilot pharmacogenomic program in identifying genetic variation
to predict the safety, toxicity and/or efficacy of drugs. DNA will be extracted from
patients' peripheral blood to study SNPs in DPD, TS, MTHFR, UGT1A1, CYP3A4, CYP3A5, GSTM1,
GSTT1, GSTP1, HO-1, ERCC1, XPD, XRCC1 and EGFR genes. The results of genetic study will be
compared to treatment efficacy and toxicity. The ultimate goal is to use genotype profiles
to provide individualized cancer treatment to improve outcome and decrease toxicity.
Observational Model: Cohort, Time Perspective: Prospective
Yu-Jui Yvonne Wan, Ph.D.
University of Kansas
United States: Institutional Review Board
|University of Kansas Medical Center||Kansas City, Kansas 66160-7353|